Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced NMPA clearance to initiate a clinical study evaluating irinotecan liposome (II) in combination with oxaliplatin, 5-fluorouracil, and leucovorin versus gemcitabine plus capecitabine as adjuvant therapy following pancreatic cancer surgery. The liposomal irinotecan formulation, which received initial NMPA approval in 2023 for metastatic pancreatic cancer post-gemcitabine progression, now expands into the curative-intent adjuvant setting, targeting the high-risk population where ~80% of patients relapse within 2 years despite surgery.
Regulatory Milestone
Item
Detail
Agency
National Medical Products Administration (NMPA)
Approval Type
Clinical trial authorization (IND)
Product
Irinotecan liposome (II)
Drug Class
Liposomal irinotecan hydrochloride injection
Mechanism
Topoisomerase I inhibitor; induces reversible single-strand DNA breaks
Study Design
Irinotecan liposome + oxaliplatin/5-FU/leucovorin vs. gemcitabine/capecitabine
~25,000 patients/year eligible for adjuvant therapy; high unmet need for improved regimens
Competitive Landscape
Gemcitabine/capecitabine standard; modified FOLFIRINOX (high toxicity) for fit patients; liposomal irinotecan offers middle ground
Hengrui Positioning
Extends irinotecan liposome franchise from palliative to curative setting; lifecycle management
Global Ambitions
Adjuvant data could support U.S./EU label expansion; differentiate from Onivyde metastatic-only indication
Study Design & Comparator
Arm
Regimen
Rationale
Experimental
Irinotecan liposome (II) + oxaliplatin + 5-FU + leucovorin
Liposomal irinotecan replaces standard irinotecan; enhanced tolerability and efficacy
Control
Gemcitabine + capecitabine
Current China standard of care (ESPAC-4 based)
Setting
Post-surgical adjuvant
Micro-metastatic disease eradication
Primary Endpoint
Disease-free survival (anticipated)
Standard adjuvant oncology endpoint
Competitive Dynamics
Regimen
Components
Status
Hengrui Liposomal Irinotecan Advantage
Gemcitabine/capecitabine
Nucleoside analogs
Standard adjuvant
Liposomal delivery; topoisomerase I mechanism
Modified FOLFIRINOX
Oxaliplatin/irinotecan/5-FU/leucovorin
High-efficacy, high-toxicity option
Improved irinotecan tolerability via liposomal formulation
Onivyde (originator)
Liposomal irinotecan
Metastatic only (China)
Hengrui adjuvant development first-in-class for liposomal irinotecan
Hengrui
Irinotecan liposome (II) + FOLFOX
Phase II adjuvant
Potential for superior DFS with manageable toxicity
Development Outlook
Phase
Timeline
Objectives
Phase II
2026-2028
Safety/tolerability of liposomal irinotecan in adjuvant setting; disease-free survival signal
Phase III
2028-2032
Registrational study vs. gemcitabine/capecitabine; overall survival secondary endpoint
Regulatory Strategy
2032-2033
China NDA adjuvant indication; U.S./EU sNDA potential
Global Positioning
2028+
First liposomal irinotecan adjuvant data; potential best-in-class pancreatic adjuvant therapy
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, adjuvant efficacy signals, and competitive positioning for irinotecan liposome (II) in pancreatic cancer. Actual results may differ due to surgical patient selection variability, adjuvant therapy tolerability challenges, and competitive dynamics with FOLFIRINOX.-Fineline Info & Tech
By Fineline Cube